Luke Ralston, a biomedical engineer and scientific reviewer at the FDA, has emphasised the need for transparency in AI regulation. The two main issues hampering the regulation are performance drift and data generalisation. Ralston stated that AI companies need to start monitoring and tracking the performance of their products once deployed and they also need to expand its representative data to cover more than just the demographics.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
